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Gene therapyThe neuronal ceroid lipofuscinoses (NCL, Batten disease) are a group of inherited neurodegenerative diseases.
Infantile neuronal ceroid lipofuscinosis (INCL, infantile Batten disease, or infantile CLN1 disease) is caused by
a deﬁciency in the soluble lysosomal enzyme palmitoyl protein thioesterase-1 (PPT1) and has the earliest
onset and fastest progression of all the NCLs. Several therapeutic strategies including enzyme replacement,
gene therapy, stem cell-mediated therapy, and small molecule drugs have resulted in minimal to modest im-
provements in the murine model of PPT1-deﬁciency. However, more recent studies using various combina-
tions of these approaches have shown more promising results; in some instances more than doubling the
lifespan of PPT1-deﬁcient mice. These combination therapies that target different pathogenic mechanisms
may offer the hope of treating this profoundly neurodegenerative disorder. Similar approaches may be useful
when treating other forms of NCL caused by deﬁciencies in soluble lysosomal proteins. Different therapeutic
targets will need to be identiﬁed and novel strategies developed in order to effectively treat forms of NCL
caused by deﬁciencies in integral membrane proteins such as juvenile neuronal ceroid lipofuscinosis. Finally,
the challenge with all of the NCLs will lie in early diagnosis, improving the efﬁcacy of the treatments, and ef-
fectively translating them into the clinic. This article is part of a Special Issue entitled: The Neuronal Ceroid
Lipofuscinoses or Batten Disease.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Infantile neuronal ceroid lipofuscinosis (INCL, infantile Batten dis-
ease, or infantile CLN1 disease) is a rapidly progressing lysosomal stor-
age disorder (LSD) caused by defects in the gene coding for palmitoyl
protein thioesterase-1 (CLN1) [42]. This soluble lysosomal enzyme is re-
sponsible for cleaving long-chain fatty acid residues from cysteine resi-
dues on amultitude of protein targets [26,27,41]. In the absence of PPT1
activity, undegraded substrates accumulate in both CNS and systemic
tissues. Infantile CLN1 disease can be distinguished ultrastructurallyronal Ceroid Lipofuscinoses or
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l rights reserved.from other forms of NCL by the accumulation of granular osmiophilic
deposits in the CNS and in cultured ﬁbroblasts. A hallmark of the
NCLs, including infantile CLN1 disease, is the progressive accumulation
of autoﬂuorescent material (lipofuscin), most notably in the nervous
system, but which is also found in some other tissues [33]. Profound
neuronal degeneration, cortical thinning, and overall brain atrophy are
prominent features of infantile CLN1 disease [14,15]. The mass of an af-
fected child's brain at autopsy may be only 50% of a comparably aged
normal child.
Children with infantile CLN1 disease generally develop symptoms
around 18 months of age, which include visual defects and blindness,
motor and cognitive deﬁcits, seizures and ultimately early death
[36,46]. No treatment or cure is currently available for these children.
Two mouse models of infantile CLN1 disease were developed that
are completely deﬁcient in PPT1 activity [13,18]. These animals reca-
pitulate many features of the human disease including progressive
neurodegeneration, cortical thinning, brain atrophy, autoﬂuorescent
accumulation, retinal dysfunction, spontaneous seizures, motor deﬁ-
cits and shortened lifespan [1,11,13]. These mice are accurate
phenocopies of the human disease and are valuable tools for studying
disease pathogenesis and testing treatment strategies.
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been greatly accelerated by the availability of accurate mouse models.
Unfortunately, few single therapies have provided any extension in
lifespan, and as described below, any improvements observed using
single therapies have been rather modest. However, emerging data
from combination therapies for various LSDs, and in infantile CLN1
disease in particular, suggest that this approach offers much promise
for treating this intractable disease.
2. Enzyme replacement therapy
Enzyme replacement therapy, or ERT, is a conceptually simplemeth-
od for treating an enzyme deﬁciency. Enzyme replacement therapy
takes advantage of the fact that lysosomal enzymes can be secreted by
cells and taken up by neighboring cells through a receptor-mediated
process; either themannose-6-phosphate or themannose receptor sys-
tems [20]. This process was originally referred to as ‘cross-correction’
[31]. Recombinant enzyme that is post-translationally glycosylated
and contains terminal mannose or mannsose-6-phosphate residues
will be endocytosed by cells in vivo following an injection. Enzyme re-
placement therapy is relatively effective at treating the systemic disease
associated with several other lysosomal storage diseases following in-
travenous injection. This approach had not, until recently, been
attempted in infantile CLN1 disease due to its predominantly neurolog-
ical pathology. Lysosomal enzymes, in general, do not cross the blood
brain barrier (BBB) effectively. Although some systemically delivered
recombinant human PPT1 (rhPPT1) does appear to cross the BBB in
the mouse model of infantile CLN1 disease, this was in very small
amounts [17]. Nonetheless, intravenous rhPPT1 delivery was tested
for tolerability, tissue distribution, and efﬁcacy in Ppt1−/−mice. Levels
of PPT1 activity reached near normal levels in the visceral tissues of
treated Ppt1−/− mice. As expected, levels of PPT1 activity in the brain
remained quite low, although at high dose a small amount of activity
was seen at 2 h post-injection. Unfortunately, PPT1 activity was
undetectable in the brain by 24 h post-injection [25]. However, system-
ically ERTmight be able to reduce the disease burden in visceral organs
and thus have a positive impact on disease course. Indeed, the animals
receiving weekly intravenous injections of rhPPT1 from birth had
some improvements in neuropathology and signiﬁcant autoﬂuorescent
clearance in visceral tissues [25]. Importantly, these animals also had a
modest, but signiﬁcant increase in lifespan from 236 to 271 days, and
a similar improvement in motor function. Although intravenous deliv-
ery of ERTwill likely be ineffective as a stand-alone therapy for infantile
CLN1 disease, it may be very effective at treating the systemic disease as
part of a combination approach including CNS-targeted therapies. Alter-
natively, chronic delivery of recombinant enzyme to the CNS through
an implantable pump or periodic intrathecal injections might provide
signiﬁcant beneﬁt to the CNS. This approach has resulted in improve-
ments in the CNS in animal models and is being tested in children
with different lysosomal enzyme deﬁciencies [6,7,16,23,28,43].
3. Bone marrow transplantation
Bone marrow transplantation (BMT) or hematopoietic stem cell
transplantation (HSCT) has each been employed to treat LSDs for de-
cades. The efﬁcacy of this approach varies with respect to the speciﬁc
lysosomal storage disease, as well as the age when the transplant is
initiated. Like ERT, this approach largely relies on the phenomenon
of cross-correction [31]. It is believed that a small number of normal
donor cells of hematopoietic origin can migrate into the brain and
supply enzyme to a large number of deﬁcient host cells. Unfortunate-
ly, both pre-clinical and clinical experience with BMT alone has prov-
en ineffective for infantile CLN1 disease [5,21,22,29]. In fact, not only
is there no increase in lifespan but also there is a deterioration in
motor function in PPT1-deﬁcient mice treated with BMT during the
neonatal period [29].4. Gene therapy
Intracranial gene therapywas ﬁrst attempted in Ppt1−/−mice utiliz-
ing a ﬁrst-generation adeno-associated virus (AAV) vector (AAV2)
injected in two locations per hemisphere in the forebrain [10]. A
reduction in autoﬂuorescent storage material, as well as increase in
the brain mass and cortical thickness were reported. Further investiga-
tion demonstrated that CNS-directed gene therapy is more efﬁcacious
when the cerebellum is targeted along with the forebrain [12]. Signiﬁ-
cantly greater enzyme activity and reductions in autoﬂuorescent accu-
mulation, as well as increased in brain weight were observed with
this improved strategy. Importantly, the combination of forebrain and
cerebellar injections resulted in improvements in motor function and
decreased seizure activity. Unfortunately, there was no signiﬁcant
increase in lifespan. In a related study, Ppt1−/− mice were injected
intravitreally with the same AAV2-PPT1 vector [11]. The infantile
CLN1 disease mice receiving eye-directed gene therapy demonstrating
marked improvements in both retinal pathology and function. Interest-
ingly, intravitreal injections allowed for anterograde axonal transport
of PPT1 activity into the brains of treated mice and decreased
neurodegeneration throughout the optic tracts [11]. This approach,
perhaps combined with direct intracranial injections could provide
more widespread delivery of PPT1 activity to the CNS. This is vital in a
disorder such as infantile CLN1 disease in which CNS pathology is
widespread.
A recent study in PPT1-deﬁcient mice demonstrated that bonemar-
row transplantation can synergize with CNS-directed gene transfer
to greatly enhance the efﬁcacy of either approach [29]. As mentioned
above, clinical experience has demonstrated that the NCLs are refracto-
ry to BMT [5,21,22]. This was conﬁrmed in the mouse model of INCL,
since Ppt1−/− mice receiving BMT had identical lifespans as untreated
animals (median ~35.5 weeks). Treatment with a second-generation
AAV vector (AAV2/5) alone resulted in a median lifespan of
~54 weeks. This clearly demonstrates the value of increased PPT1
distribution and expression. Interestingly, and quite surprisingly,
animals receiving both AAV2/5-mediated, CNS-directed gene thera-
py and BMT had a median lifespan of ~74 weeks. This increase in
lifespan is coupled with signiﬁcant improvements in motor function,
with combination-treated animals performing nearly normally until
~56 weeks of age. Consistent with the improved lifespan and behav-
ioral measures, signiﬁcant improvements in histological markers of
disease were also observed. Although the mechanism of synergy be-
tween gene therapy and BMT is not currently known, this strategy
holds promise for the treatment of this invariably fatal neurodegen-
erative disease.5. Neuronal stem cells
The advancements in recent years in stem cell technology have
raised the possibility that neuronal stem cell transplantation might
be a viable treatment strategy for infantile CLN1 disease. Stem
cells isolated from the human central nervous system have been cul-
tured, puriﬁed and banked [38,40]. These cells were successfully
transplanted into the brains of immunodeﬁcient NOD-SCID mice,
which will not reject the human cells [38]. When normal (PPT1-
positive) human neuronal stem cells were transplanted into PPT1-
deﬁcient mice on the NOD-SCID background, the cells engrafted
and migrated widely throughout the brain [39]. Interestingly,
these cells provided sufﬁcient levels of PPT1 activity to decrease
autoﬂuorescence, delay loss of host neurons and improve motor
function. These pre-clinical data were used to support a phase one
neuronal stem cell clinical trial in infantile CLN1 disease and late
infantile CLN2 disease children. Although some safety concerns
remain, neuronal stem cell therapy may be an appropriate treat-
ment for infantile CLN1 disease and other LSDs.
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Small molecule drugs that effectively treat LSDs in general have
been elusive. Most small molecule drug treatments tend to target
downstream effects of disease, and therefore have limited efﬁcacy.
However, two small molecule drugs have shown promise in both
cell and whole animal models of infantile CLN1 disease and may be
useful as stand-alone treatments or, more likely, as adjunct therapies
in combination with other approaches.
6.1. Resveratrol
Resveratrol, an antioxidant compound derived from the skins of red
grapes, has been shown to decrease oxidative stress and apoptotic
markers in cultured cells froman infantile CLN1 disease patient [50]. Ox-
idative and ER stress have been identiﬁed in many LSDs, including INCL
[44], where it is known to activate the caspase 9 apoptotic pathway
[19,44]. Furthermore, PPT1 deﬁciency leads to disruption of energy me-
tabolism [45,47], presumably related to the ER and oxidative stress. In
both PPT1-deﬁcientﬁbroblasts andmice, treatmentwith resveratrol im-
proved the energy proﬁle and reduced apoptotic markers [45]. Further-
more, Ppt1−/− mice treated with resveratrol in their diet had a
signiﬁcant increase in lifespan, from ~34 weeks to ~37 weeks [45]. Al-
though this increase is relatively small, it is nonetheless impressive
given the fact that resveratrol does not target the primary cause of dis-
ease, PPT1-deﬁciency. Additionally, resveratrol may reduce BBB perme-
ability in INCL through its anti-inﬂammatory effects [35]. The BBB is
somewhat ‘leaky’ in infantile CLN1 disease and it has been suggested
that this is due the actions of TH17-lymphocytes and their secretion of
matrix metaloproteases, which may degrade tight junctions needed to
maintain the barrier [35].
6.2. Cysteamine
Lysosomotropic drugs that have similar chemical actions to PPT1
have been proposed as a possible treatment for infantile CLN1 disease
since they can localize to the lysosome and cleave thioester linkages
similar to PPT1 [51]. Phosphocysteamine is a small molecule drug that
meets those criteria. Furthermore, phosphocysteamine is capable of
crossing the BBB, which is of obvious importance in INCL [51]. Cultured
human lymphoblasts from infantile CLN1 disease patients treated with
phosphocysteamine had greatly reduced storage material compared to
cells treated with vehicle [51]. While in vitro data clearly demonstrate
that phosphocysteamine is not as effective at disrupting thioester link-
ages as PPT1 [24], this remains a potentially viable therapeutic ap-
proach. The drug may be able to reduce the load of accumulating
products enough to delay disease progression, andmight be particularly
effective when combined with therapies directed at the root cause of
disease. Recently, phosphocysteamine was tested in the mouse model
of PPT1-deﬁciency, both alone and in combination with CNS-directed
gene therapy using an AAV2/5 vector [34]. These animals tolerated
the therapy well, and were analyzed through behavioral tests as well
as histological assessments. As described above, CNS-directed gene
therapy provided persistent and signiﬁcant improvements in lifespan,
motor function and histological markers of disease. In contrast,
phosphocysteamine alone provided a small and transient improvement
in motor function. Additionally, animals receiving phosphocysteamine
alone did not have any increase in lifespan or improvements in pathol-
ogy. The addition of phosphocysteamine to CNS-directed gene therapy
did not further improve pathology or lifespan, but did provide addition-
al beneﬁt in motor function [34]. This is promising as it indicates that
some clinical beneﬁt can be gained through phosphocysteamine thera-
py, at least in the area of quality of life. Consistent with the pre-clinical
data obtained in themurinemodel of infantile CLN1 disease, the results
of a recent clinical trial in children with INCL showed that systemic
treatment with phosphocysteamine provided little clinical beneﬁt [9].However, it remains possible that the addition of this treatment to
more complex combination therapy approaches (e.g. gene therapy +
BMT or gene therapy + ERT) may provide even greater beneﬁt.
7. Other neuronal ceroid lipofuscinoses
Infantile neuronal ceroid lipofuscinosis is one member of the NCL
family of neurodegenerative diseases. There are several other forms of
NCL caused by a deﬁciency in a soluble lysosomal enzyme. The most
common is late infantile neuronal ceroid lipofuscinosis (LINCL, late in-
fantile Batten disease, or late infantile CLN2 disease), which is caused
by a deﬁciency in the lysosomal enzyme tripeptidyl peptidase 1
(TPP1). Since both late infantile CLN2 disease and infantile CLN1 disease
share a common defect (soluble lysosomal enzyme deﬁciency), similar
therapeutic strategies might be effective for both. In fact, it has been
shown that intracerebroventricular or intrathecal administration of re-
combinant TPP1 reduces neuroinﬂammation, decreases the accumula-
tion of autoﬂuorescent material, and improves the clinical course of
disease in the murine model of late infantile CLN2 disease [3,49]. En-
couragingly, intrathecal administration of recombinant TPP1 also re-
duces lysosomal storage in a large animal model (canine) of late
infantile CLN2 disease [43]. Interestingly, intravenous administration
of recombinant TPP1 also results in ~10% normal levels of enzyme in
the CNS [30]. Central nervous system-directed gene therapy using
AAV vectors expressing TPP1 has also shown promise in the late infan-
tile CLN2 disease mouse [2,32]. These pre-clinical experiments led to a
clinical trial using an AAV2 vector in children with late infantile CLN2
disease [48]. Although there was little beneﬁt observed in the treated
children, this approach was well tolerated. It should be noted that this
was designed as a safety trial performed in severely affected children.
The use of improved AAV vectors in early stage or pre-symptomatic
children might provide some clinical beneﬁt. Although these data are
promising single treatments have led to only partial correction of late
infantile CLN2 disease, similar to the results in infantile CLN1 disease.
It would be interesting to determine the efﬁcacy of combination treat-
ments in late infantile CLN2 disease.
A number of NCLs are caused by deﬁciencies in integral membrane
proteins that are not secreted and, therefore, cannot correct sur-
rounding cells in a manner similar to the soluble lysosomal enzymes.
Juvenile neuronal ceroid lipofuscinosis (JNCL, juvenile Batten disease,
or juvenile CLN3 disease) is the most common form of NCL and is
caused by a deﬁciency of an integral membrane protein of unknown
function. Since the protein cannot “cross-correct” adjacent cells and
the function is unknown, it has been extremely difﬁcult to devise or
even envision an effective therapeutic strategy. However, it might
be possible to target secondary pathogenic mechanisms and decrease
the severity of the disease. It has been shown that the mouse model of
juvenile CLN3 disease and children with the disease develop autoan-
tibodies to several proteins, including glutamic acid decarboxylase
(GAD65) [4]. It has also been shown that immunosuppression with
mycophenolate decreases the neuroinﬂammation and improves
motor function in the mouse model of juvenile CLN3 disease [37]. A
clinical trial in JNCL children using mycophenolate has been initiated.
However, much more research will be required to determine the
function of the protein deﬁcient in juvenile CLN3 disease and develop
effective therapies for this invariably fatal disorder.
8. Conclusions
Infantile CLN1 disease has, until recently, been refractory to most
therapeutic interventions. This is likely due to the fact that the CNS is
difﬁcult to effectively target. However, it is also possible that providing
therapy exclusively to the CNS could limit efﬁcacy. It is known that PPT1
is expressed in virtually every cell type and there is histologic evidence
of disease in multiple organ systems, including the heart [8]. With the
more recent development of an appropriate mouse model and better
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options have been progressing steadily. Although single therapies have
generally resulted in modest improvements, the dramatic synergy ob-
served through combining CNS-directed gene therapy and BMT suggests
that combinatorial approachesmay be the best strategy for treating INCL.
Since infantile CLN1 disease has an early onset (6 months–1 year) and
rapid progression (death typically by 3–6 years of age), early diagnosis,
perhaps through a newborn screening program, will greatly enhance
the efﬁcacy of any therapeutic intervention. Other forms of NCL caused
by deﬁciencies in soluble lysosomal will likely respond to similar ap-
proaches as those being developed for infantile CLN1 disease. Unfortu-
nately, NCLs caused by deﬁciencies in integral membrane proteins will
require much more research in order to understand the function of the
various proteins and to devise effective therapeutic strategies.
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